Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caldonirimab plus nimotuzumab in recurrent or metastatic cervical cancer
NCT05606263Phase 2Unknown
- Sponsor
- Xi'an Jiaotong University
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Cervical Cancer (CC), sponsored by Xi'an Jiaotong University. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05606263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606263.